Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.23 | -$8.22 | -33.62% | 815.5K | $2.4B | $10.42$138.81 |
| AGRZ | Agroz | $2.39 | -$1.10 | -31.52% | 290.7K | $75.6M | $2.08$7.20 |
| ICHR | Ichor | $15.77 | -$7.15 | -31.20% | 173.4K | $786.8M | $13.12$36.48 |
| JELD | Jeld-wen | $2.90 | -$1.31 | -31.07% | 320.7K | $358.7M | $2.32$11.66 |
| FLYE | Fly-E Group | $7.14 | -$2.86 | -28.60% | 94.4K | $189.0M | $6.85$166.00 |
| FORD | Forward Industries | $10.48 | -$3.50 | -25.04% | 128.2K | $1.2B | $3.32$46.00 |
| ESLA | Estrella Immunopharma | $2.29 | -$0.76 | -24.92% | 854.1K | $113.1M | $0.70$3.15 |
| ADTN | Adtran | $7.95 | -$2.48 | -23.78% | 409.1K | $834.9M | $6.02$12.44 |
| SOUX | Tidal Trust II - Defiance Daily Target 2x Long Soun ETF | $34.34 | -$10.48 | -23.38% | 397.8K | - | $19.16$78.10 |
| OKLL | Tidal Trust II - Defiance Daily Target 2x Long Oklo ETF | $51.50 | -$15.41 | -23.03% | 2M | - | $16.09$169.96 |
Related Articles
Featured Article
Is This Stock a Buy After Soaring by 20% in 1 Day?
Prosper Junior Bakiny|Jul 24, 2025
With Its Kpler Deal on the Rocks, Can Spire Stock Survive?
Rich Smith|Mar 16, 2025
If you pay close enough attention to conference calls, you just might find a stock that can double -- like Spire Global.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.
1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi|Mar 13, 2024
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi|Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.
Is It Too Late to Buy Sarepta Therapeutics Stock?
Prosper Junior Bakiny|Feb 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
2 Magnificent Growth Stocks to Buy With $500
Prosper Junior Bakiny|Feb 15, 2024
No need to break the bank to invest in promising stocks.
